WNT Stock Overview
WntResearch AB, a biotech company, develops therapies to prevent the metastatic process.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
WntResearch AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.067 |
| 52 Week High | kr0.42 |
| 52 Week Low | kr0.063 |
| Beta | 0.45 |
| 1 Month Change | 0% |
| 3 Month Change | 3.08% |
| 1 Year Change | -78.32% |
| 3 Year Change | -91.63% |
| 5 Year Change | -99.08% |
| Change since IPO | -99.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| WNT | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 0% | -1.0% | -1.7% |
| 1Y | -78.3% | -6.3% | 8.1% |
Return vs Industry: WNT underperformed the Swedish Biotechs industry which returned -6.3% over the past year.
Return vs Market: WNT underperformed the Swedish Market which returned 8.1% over the past year.
Price Volatility
| WNT volatility | |
|---|---|
| WNT Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: WNT has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine WNT's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 3 | Per Goran Norlen | www.wntresearch.com |
WntResearch AB, a biotech company, develops therapies to prevent the metastatic process. The company develops Foxy-5, a peptide, which is in Phase II clinical trials that reduced the risk of metastasis in patients with colon cancer. It is also developing Box-5, a WNT5A antagonist for the treatment of malignant melanoma, and pancreatic and gastric cancer.
WntResearch AB Fundamentals Summary
| WNT fundamental statistics | |
|---|---|
| Market cap | kr26.86m |
| Earnings (TTM) | -kr32.47m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs WNT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WNT income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr32.47m |
| Earnings | -kr32.47m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 03, 2024
| Earnings per share (EPS) | -0.081 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did WNT perform over the long term?
See historical performance and comparison